Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
about
Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program.Dietary macronutrient and energy intake and urinary incontinence in women.Benign prostatic hyperplasia: from bench to clinicProstate-associated gene 4 (PAGE4) protects cells against stress by elevating p21 and suppressing reactive oxygen species productionAssociation of variants in genes related to the immune response and obesity with BPH in CLUE IIDietary macronutrient intake and lower urinary tract symptoms in women.Increased risk of benign prostate hyperplasia in sleep apnea patients: a nationwide population-based study.Thiazolidinedione and Metformin Use and the Risk of Benign Prostate Hyperplasia in Veterans with Diabetes Mellitus.Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer.Genetic Determinants of Metabolism and Benign Prostate Enlargement: Associations with Prostate Volume.Does Inflammation Mediate the Obesity and BPH Relationship? An Epidemiologic Analysis of Body Composition and Inflammatory Markers in Blood, Urine, and Prostate Tissue, and the Relationship with Prostate Enlargement and Lower Urinary Tract Symptoms.Future perspectives of prostate cancer therapy.Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trialShould modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia?Role of interleukins, IGF and stem cells in BPHBenign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions.A green and black tea extract benefits urological health in men with lower urinary tract symptoms.The link between benign prostatic hyperplasia and prostate cancer.Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials.Etiology of chronic prostatitis/chronic pelvic pain syndrome: psychoimmunoneurendocrine dysfunction (PINE syndrome) or just a really bad infection?Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome.Association between chronic obstructive pulmonary disease and increased risk of benign prostatic hyperplasia: a retrospective nationwide cohort study.The effect of non-steroidal anti-inflammatory drugs on risk of benign prostatic hyperplasia.Serum amyloid A, phospholipase A₂-IIA and C-reactive protein as inflammatory biomarkers for prostate diseases.Lipidosterolic extract of serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells.Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and -2.Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial.Rural vs. urban disparities in association with lower urinary tract symptoms and benign prostatic hyperplasia in ageing men, NHANES 2001-2008.DNMT1 regulates IL-6- and TGF-β1-induced epithelial mesenchymal transition in prostate epithelial cells.Non-alcoholic fatty liver disease is associated with benign prostate hyperplasia in men and with overactive bladder in women.Inhibitory Effect of Thymoquinone on Testosterone-Induced Benign Prostatic Hyperplasia in Wistar Rats.The effects of statins on benign prostatic hyperplasia in elderly patients with metabolic syndrome.Office evaluation of male patients with lower urinary tract symptoms.Epidemiology of clinical benign prostatic hyperplasia.Protective effect of hydroxyfasudil, a Rho kinase inhibitor, on ventral prostatic hyperplasia in the spontaneously hypertensive rat.Metabolic syndrome and benign prostatic hyperplasia: An update.Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia
P2860
Q31001228-930338C9-356C-4B5E-BE1B-07C6F880D076Q33880849-70F4FD52-B06F-43F8-955E-D1388E0149B9Q34216723-AEC153AD-7D10-4835-A4F3-F785C6540155Q34448124-F7A3B01F-E1B4-48A2-B0A3-4F22ACCD033BQ34490355-F35DD5A0-EEC5-4F6C-A5BF-B001BF83A02AQ34959268-227258B6-4852-4EF6-AB17-19548406E8A8Q35131466-46A2AA79-90FA-4987-8DB7-811E6998C9E9Q35190607-4C2592A2-601D-4F1D-A506-502C40AE5541Q35318562-1060C0A6-E533-4E2D-BD93-0E5879A7F3FCQ35687087-8632DD53-8BD8-4A97-9BA1-6E6FDA1844E4Q36059979-802F0106-FE94-48C7-BA3E-BF2C65D36B9BQ36076453-0FE2B2FE-DA58-4F05-A1A8-D0F2700D7BC1Q36383682-AE0964A1-D1ED-4414-A7BE-4BB9C247B372Q37127902-1E81088D-DBF9-47F4-925F-31455E5FFC64Q37416239-8D2BA1E5-20B3-40D0-98F8-C9AEBEC7A8F4Q37618958-4EE77C20-4BBE-4C5B-B43A-5C29002B7CC6Q37730835-2653E07F-1685-4EFD-84DD-9D9366C5BEC7Q38061029-891D0179-E792-4B96-A424-8F31851FCD92Q38077302-A3CFCF75-6FDC-4CA5-BBB8-53B834CC3727Q38098399-AFC54AA7-DCC2-4D5E-A77E-BFED5F8FCC0CQ38692706-170FF6E1-1ED8-4459-B6A6-24A73F5ADFBEQ38711334-8D4BF737-D05A-418E-92A5-E1A3AFBBD570Q38798979-95F45751-8BE0-46DD-912C-5CC8DFAC9571Q39092660-E6DD4DC4-4D2A-4141-9475-E8D388591C8EQ39127025-3D4171AC-DB48-43CB-82E8-18A56E5E6DC0Q39264604-6755048B-1356-4408-8981-C2A43B4A8BAEQ39981630-A53FB915-C9D4-4AA2-B031-81659ABF46EFQ40300137-BD8D35CF-2CFF-4569-AA8E-0D43F1A323B7Q42264513-0BF53555-8DC5-4522-8CC3-7021B7BFA9A7Q45901789-0040B4B0-7F0D-4593-8542-0182B1C9D050Q48271761-67C4CF06-6F37-46F5-96FC-32E2DEC7CBEAQ49117373-BFC08AEA-FC09-4A33-B160-4343D81F2D1CQ51317315-F384121B-51DB-4D72-BA17-0568509F1328Q51776590-F74F2C1E-D206-4E6D-8E7D-DBAC7CDC5B8CQ52923562-404EEFE4-5994-4171-A83C-52890992DDC0Q55345009-F294B319-BC94-4EFE-8F51-BA90729B82E8Q56898498-FB90859C-98D3-451A-8640-911A4CA2A492
P2860
Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Biomarkers of systemic inflamm ...... state cancer prevention trial.
@ast
Biomarkers of systemic inflamm ...... state cancer prevention trial.
@en
type
label
Biomarkers of systemic inflamm ...... state cancer prevention trial.
@ast
Biomarkers of systemic inflamm ...... state cancer prevention trial.
@en
prefLabel
Biomarkers of systemic inflamm ...... state cancer prevention trial.
@ast
Biomarkers of systemic inflamm ...... state cancer prevention trial.
@en
P2093
P2860
P356
P1476
Biomarkers of systemic inflamm ...... state cancer prevention trial.
@en
P2093
Catherine M Tangen
Daniel W Lin
Emily White
Ian M Thompson
Jeannette M Schenk
Marian L Neuhouser
Mario Kratz
P2860
P304
P356
10.1093/AJE/KWP406
P407
P577
2010-02-08T00:00:00Z